Research Paper Volume 12, Issue 5 pp 4641—4659
Effects of the probiotic formulation SLAB51 in in vitro and in vivo Parkinson’s disease models
- 1 Department of Life, Health and Environmental Sciences, University of L’Aquila, 67100 L’Aquila, Italy
- 2 Department of Medical Biotechnology, University of Siena, Siena, Italy
- 3 Sbarro Institute for Cancer Research and Molecular Medicine and Center for Biotechnology, Temple University, Philadelphia, PA 19122, USA
Received: December 17, 2019 Accepted: March 4, 2020 Published: March 9, 2020
https://doi.org/10.18632/aging.102927How to Cite
Copyright © 2020 Castelli et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
Parkinson is a common neurodegenerative disorder, characterized by motor and non-motor symptoms, including abnormalities in the gut function, which may appear before the motor sign. To date, there are treatments that can help relieve Parkinson’ disease (PD)-associated symptoms, but there is no cure to control the onset and progression of this disorder. Altered components of the gut could represent a key role in gut-brain axis, which is a bidirectional system between the central nervous system and the enteric nervous system. Diet can alter the microbiota composition, affecting gut-brain axis function. Gut microbiome restoration through selected probiotics’ administration has been reported. In this study, we investigated the effects of the novel formulation SLAB51 in PD. Our findings indicate that this probiotic formulation can counteract the detrimental effect of 6-OHDA in vitro and in vivo models of PD. The results suggest that SLAB51 can be a promising candidate for the prevention or as coadjuvant treatment of PD.